<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335448</url>
  </required_header>
  <id_info>
    <org_study_id>EPOCH</org_study_id>
    <nct_id>NCT04335448</nct_id>
  </id_info>
  <brief_title>Comprehensive Long-term Follow up of Adults With Arterial Switch Operation</brief_title>
  <acronym>EPOCH-ASO</acronym>
  <official_title>Comprehensive Long-term Follow up of Adults With Arterial Switch Operation - European Collaboration for Prospective Outcome Research in Congenital Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Long-term outcomes in adults with prior arterial switch operation (ASO) have not
      yet been well defined. The aim of this study is to elucidate incidence and predictors of
      adverse cardiac outcomes in a prospectively followed cohort of adults after their ASO.

      Methods: The comprehensive long-term follow up of adults with ASO is a project within the
      European collaboration for prospective outcome research in congenital heart disease (EPOCH).
      It is designed as a prospective, international multicenter cohort study. Consecutive patients
      (aged 16 years or more) with prior ASO will be included at 11 European tertiary care centers.
      Participants will be followed according to a standardized protocol following international
      recommendations, including standardized protocols for imaging and for exercise testing. Main
      outcome measures are all-cause and cardiac-related mortality, rate of cardiac
      re-intervention, neo-aortic dissection, myocardial infarction, stroke, infective
      endocarditis, sustained atrial and ventricular arrhythmias, new-onset or worsening pulmonary
      hypertension and new-onset heart failure. Secondary endpoints are frequency and progression
      of right ventricular outflow tract stenosis, neo-aortic root dilatation, neo-aortic valve
      regurgitation and ventricular dysfunction. The impact of demographic, anatomic (e.g. coronary
      artery anatomy) and functional variables on the above-mentioned outcomes, as well as quality
      of life and incidence of pregnancy related complications will also be assessed.

      Aim: The prospective, international, multicenter EPOCH-ASO study will provide a better
      understanding of adverse outcomes and their predictors in adults after ASO. The results of
      the EPOCH-ASO study may help to optimize future care of this novel patient cohort in adult
      cardiology.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">September 30, 2039</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2039</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>20 Years</target_duration>
  <primary_outcome>
    <measure>Incidence of all-cause mortality</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Determination of cause of death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of cardiac-related mortality</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Sudden cardiac death (death that ensues unexpected within one hour of onset of symptoms), death related to acute myocardial infarction, death that is primarily caused by heart failure or death within 30 days or during the hospital admission after a cardiac intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence/rate of re-intervention</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Includes all types of cardiac re-intervention with detailed analysis of the indication of re-intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence/rate of neo-aortic dissection</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Aortic dissection with entry within the neo-aortic root.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of myocardial infarction</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Defined according to the Fourth Universal Definition of Myocardial Infarction. Defined according to the Fourth Universal Definition of Myocardial Infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of arrhythmias</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Atrial arrhythmias with a duration of &gt;30 seconds, or requiring anti-arrhythmic medication or ablation procedures and / or sustained ventricular tachycardia (heart rate &gt;100/min) for at least 30 seconds or requiring electrical cardioversion / defibrillation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of new onset / worsening heart failure</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Hospital admission for heart failure or initiation of heart failure medication for symptoms of heart failure (excludes initiation of medication for asymptomatic deterioration of ventricular function), according to the current guidelines of the European Society of Cardiology.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of stroke</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Focal neurological symptoms and confirmation of cerebral ischemia or infarction by cerebral magnetic resonance imaging or computed tomography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of infective endocarditis</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Defined according to the modified Duke's criteria, according to the current ESC guidelines.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of pulmonary hypertension</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Defined as an increase in mean pulmonary arterial pressure (PAPm) â‰¥20 mmHg at rest as assessed by right heart catheterization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of right ventricular outflow tract stenosis</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>At least 1 of the following criteria:
Branch pulmonary artery minimal diameter: maximal diameter at least 1:2 on CT or MRI
Echocardiographic systolic peak gradient across branch pulmonary arteries &gt; 16mmHg (peak velocity &gt; 2.0m/s)
Estimated right ventricular systolic pressure &gt; 40mmHg (determined by RV/RA-pressure gradient and estimated central venous pressure, see echocardiography protocol for details)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of the different patterns of the coronary anatomy</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>To study the impact of coronary artery anatomy and type of coronary reimplantation on cardiovascular morbidity, ventricular function and functional capacity with a specific focus on presence of coronary artery obstruction, acute proximal angulation and inter-arterial or intramural course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence/rate of neo-aortic root dilatation</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Increase of neo-aortic root dilatation of at least 3mm, determined with the same imaging modality and appropriate side-by-side comparison of actual images.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of progression of neo-aortic root dilatation</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Increase of neo-aortic root dilatation of at least 3mm, determined with the same imaging modality and appropriate side-by-side comparison of actual images.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence/rate of neo-aortic regurgitation</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Assessment by echocardiography:
- Mild, moderate, severe (50)
Assessment by CMR
- Regurgitation fraction and volume by flow measurements in proximal aortic root.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of progression of neo-aortic regurgitation</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Increase &gt; 1 grade (echocardiography) Increase of regurgitant fraction &gt;10% on CMR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence/rate of left ventricular systolic dysfunction</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Echocardiography:
- Left ventricular ejection fraction (LVEF) biplane Simpson &lt;52% for men and &lt;54% for women (33)
CMR:
- LVEF &lt; 52%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence/rate of left ventricular diastolic dysfunction</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Echocardiography:
- Defined according to the current recommendations for the evaluation of left ventricular diastolic function by the America society of echocardiography and the European association of cardiovascular Imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of worsening left ventricular function</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Decrease of LVEF &gt;5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence/rate of Right ventricular dysfunction</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Echocardiography:
- At least 2 of the following
FAC &lt;30%
TAPSE &lt;18mm
TAPSE S' &lt;10cm/s
CMR:
- RVEF &lt; 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of worsening right ventricular function</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>Echocardiography (not valid in case of worsening tricuspid regurgitation) - At least 2 of the following:
Decrease in Fac &gt; 10%
Decrease in TAPSE &gt;5mm
Decrease in TAPSE S' &gt;3cm/s
CMR:
- Decrease in RVEF &gt;5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of poor functional capacity</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>As determined by cardiopulmonary exercise testing by measuring Lung Function (flow volume loops), oxygen consumption during exercise (VO2 max), anaerobic threshold, heart performance during exercise (O2-Heart rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pregnancy</measure>
    <time_frame>during a follow up of up to 20 years</time_frame>
    <description>To study the impact of pregnancy on mortality and cardiovascular morbidity.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Transposition of Great Vessels</condition>
  <arm_group>
    <arm_group_label>Arterial Switch Operation - Transposition of Great Arteries</arm_group_label>
    <description>Patients with previous arterial switch operation for the treatment of a transposition of great arteries will constitute the sole group of the cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention is planed</intervention_name>
    <description>No intervention is planed</description>
    <arm_group_label>Arterial Switch Operation - Transposition of Great Arteries</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults (â‰¥16 years) with transposition of great arteries or a Taussig-Bing anomaly who
        underwent repair by an ASO, and who are actively followed at one of the participating
        centers will be enrolled. Exclusion criteria are incapability of giving informed consent
        and previous heart transplant.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (â‰¥16 years)

          -  with transposition of great arteries or a Taussig-Bing anomaly

          -  who underwent repair by an ASO, and who are actively followed at one of the
             participating centers will be enrolled.

        Exclusion Criteria:

          -  Incapability of giving informed consent and previous heart transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Greutmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Greutmann, MD</last_name>
    <phone>+41 44 255 38 83</phone>
    <phone_ext>+41442553883</phone_ext>
    <email>matthias.greutmann@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Tobler, MD</last_name>
    <phone>+41 61 265 52 14</phone>
    <phone_ext>+41442553883</phone_ext>
    <email>daniel.tobler@ubs.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Gabriel, MD</last_name>
      <email>harald.gabriel@meduniwien.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Paris IdF Ouest - HEGP HÃ´pital EuropÃ©en Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magalie Ladouceur, MD. PhD.</last_name>
      <email>magalie.ladouceur@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berto J. Bouma, MD. PhD.</last_name>
      <email>b.j.bouma@amc.uva.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Dos, MD</last_name>
      <email>ldos@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pastora Gallego, MD</last_name>
      <email>antoniap.gallego.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y PolitÃ©cnico La Fe Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquin Rueda, MD</last_name>
      <email>rueda_joa@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Tobler, MD</last_name>
      <phone>+41612655214</phone>
      <email>daniel.tobler@ubs.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Schwerzmann, MD</last_name>
      <email>markus.schwerzmann@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Javier Ruperti-Repilado, MD</last_name>
      <email>javier.rupertirepilado@insel.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Geneva</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Bouchardy, MD</last_name>
      <email>Judith.Bouchardy@chuv.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Lausanne</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Bouchardy, MD</last_name>
      <email>Judith.Bouchardy@chuv.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Greutmann, MD</last_name>
      <phone>+41442553883</phone>
      <email>matthias.greutmann@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Matthias Greutmann</investigator_full_name>
    <investigator_title>PD. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>transposition of the great arteries</keyword>
  <keyword>arterial switch operation</keyword>
  <keyword>coronary artery anomaly</keyword>
  <keyword>outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Transposition of Great Vessels</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT04335448/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

